The study objective was to characterize respondents' prognostic perceptions of HIV infection and to explore how perceptions might affect medication and safe sex nonadherence.
T he prognosis of HIV infection has improved over the years of the AIDS epidemic. Although the course of HIV infection was once rapidly fatal, therapeutic advances have lengthened the time until death considerably. Since the advent of highly active antiretroviral therapy (HAART), in fact, many consider HIV infection to have become a chronic, manageable illness. The lay press has been particularly optimistic Ð``. . . a diagnosis of HIV infection . . . no longer signifies death. It merely signifies illness.'' 1 Although the medical community has been more circumspect Ð few if any suggest cure of HIV infection Ð many do refer to HIV infection as a chronic disease. 2±5 Such a characterization of the illness may lead to prognostic parallels with``mild'' chronic diseases like hypertension, diabetes mellitus, or chronic obstructive pulmonary disease, as opposed to more``severe'' chronic diseases like spinal cord injury or cancer. 6, 7 Noted changes in actual and perceived prognosis are largely attributable to results from clinical trials of HAART. 8±12 Women, persons of color, and injection drug users are significantly less likely to participate in clinical trials. 13 Secular trends suggest that these subpopulations have benefited less, or more slowly, from new treatment regimens. 10 ,14±17 Consequently, we were interested in knowing whether a group not typical of a clinical trial sample Ð comprised of more women, persons of color, and injection drug users Ð would be optimistic about their prognosis, perhaps indicating that they extend to themselves clinical trial findings more representative of other subpopulations. In addition, we wished to explore how optimism about illness, or lack thereof, might affect rates of adherence to antiretroviral therapy and sexual risk behavior.
METHODS

Subjects
Currently active clients from an HIV-specific case management organization, ActionAIDS, Inc., in Philadelphia, Pennsylvania were surveyed by mail. ActionAIDS is the largest organization of its type in Philadelphia County, providing some form of direct service to approximately 25% of HIV-infected individuals in the Philadelphia metropolitan area; 15% to 30% of its clients are enrolled in clinical trials (K. Conare, MTS, written communication, April, 2002) . ActionAIDS' database identifies clients by level of medical, mental health, and life management needs. Individuals with the highest levels of need (e.g., living in shelters, homeless, or with dementia), as defined by ActionAIDS case managers, were thought to have low probabilities of receiving and/or returning a mailed survey and were excluded, as were incarcerated clients. Following exclusions, 298 clients were found to be at least 18 years old and were mailed a survey between May and July 1999. Two of 298 surveys were returned without a forwarding address; another survey was returned by a client's family member, who reported that the intended client had died. The final potential sample, then, was 295 clients.
Procedures
All procedures followed approval of the protocol by ActionAIDS and the Committee on Studies Involving Human Beings at the University of Pennsylvania. Action-AIDS maintained considerable oversight throughout the project to assure anonymity of clients who participated.
The final questionnaire mailed to clients was devoid of identifiers. It was included in a packet that contained a letter explaining the study, noting the support of Action-AIDS, and describing the method by which investigators had obtained potential participants' names and addresses. The letter explained that participation was completely voluntary and that no change in case management would occur as a result of nonparticipation. Each survey packet contained 3 additional items: a stamped, addressed envelope; a stamped, addressed postcard; and a $5 bill. Participants were instructed to return the questionnaire to the investigators via the provided envelope. They were also instructed to send the postcard, which had its own numerical identifier. This numerical code, details of which were managed solely by ActionAIDS, provided investigators knowledge about who had and had not responded, while assuring participants that their responses remained anonymous. In the 20 days after the first mailing was sent, 3 waves of reminder mailings were sent to those who did not return identifying postcards.
Sociodemographic and HIV-related characteristics were obtained from ActionAIDS for all individuals to whom surveys were mailed. To identify potential response bias, the characteristics of those who returned an identifier postcard were compared to those who did not.
Questionnaire
Survey questions could be categorized into 4 groups of variables:
1. Sociodemographic: Self-reported responses were used to characterize sociodemographic groupings (e.g., age, sexual orientation, race) and HIV risk behavior groups (injection drug use, blood transfusion between 1979 and 1985, and/or unsafe sexual practices). 18 2. HIV-disease severity: Self-reports of subjects' most recent CD4 cell count and history of HIVrelated opportunistic infections and/or diseases were used to identify whether a subject's disease severity met the 1993 CDC definition for AIDS. 19 Self-reported CD4 counts were used because they have been reported to approximate CD4 counts obtained from medical records and to supply clinically adequate estimates for group comparisons. 20 Self-reports of subjects' most recent viral load were obtained as well. Reported viral loads were evaluated in 2 ways: log 10 -transformed; and transformed into a dichotomous variable, detectable versus undetectable, using a cutoff of 400 copies/mL. Subjects who stated that their viral load was`< 400'' or``undetectable'' were assigned an untransformed value of 200. This was due to uncertainty about the sensitivity of viral load assays used by participants (e.g., <400 vs <50).
Illness descriptors and HIV/AIDS prognosis:
The input of 4 focus groups, conducted with a total of 25 ActionAIDS clients prior to questionnaire development, was instrumental in the development of the following items. Two questions were asked of all participants: a)``Describe what you felt like when you first found out you had HIV''; and b)``Describe what your experience with HIV/AIDS is like today.'' Participants could circle as many descriptors they wished from the following, randomly ordered list of adjectives provided by focus group participants:``a second chance'';``afraid'';``anger'';``bomb'';``cautious'';``certainty'';``celebration'';``confused'';``denial'';``depression'';`d iscouraged'';``frustrated'';``gift'';``hope'';``horror'';``limbo'';``living day-to-day'';``looking ahead'';``numb'';``peace'';``ready to die'';``ready to live'';``shock'';``skeptical'';``suspended animation'';``uncertain'';``waiting to die''; and`w ishful.'' All participants were asked to``Describe how long you expect to live'' as of``today.'' Response options were: 0 =``live less than 6 months''; 1 =``live 6 months''; 2 =``live a year''; 3 =``live a few years''; 4 =``live many years but not into old age''; and 5 =``live well into old age.'' 4. Health behaviors: Participants taking antiretroviral medications were asked what percent of the time they did not take them. Response options were:``0% (I never forget)'';``1% to 5% (I rarely forget)'';``6% to 10% (I occasionally forget)'';``11% to 20% of the time (I often forget to take my medicine)'';``21% to 40% of the time (I frequently forget to take my medicine)''; and`M ore than 40% of the time (I forget to take my medicine about half the time, or more).'' A clinically meaningful rate of nonadherence was defined as forgetting >5% of the time. 21 Participants also were asked,``How often do you have sex without a condom or other barrier protection?'' Response options were:``Always (100% of the time)'';``Frequently (75% of the time)'';`O ccasionally (50% of the time)'';``Rarely (25% of the time)'';``Never (0% of the time)''; and``I don't have sex.'' Those reporting greater frequency than``never'' were defined as engaging in sexual risk behavior. Those who reported that``I don't have sex'' were removed from analysis.
Statistical Analysis
Responders were compared to nonresponders, using c 2 or t tests, and frequency distributions of responders'
self-reported variables were examined. Frequencies of responders' word descriptor selections were computed for the times after they found out about HIV seropositivity and currently, and across-time comparisons for each word descriptor were completed using c 2 tests. The mean rating for current life expectancy was computed using data from the discrete scale, after which ratings were computed for subgroups dichotomized according to the self-reported variables listed in Table 1 and compared using 2-group t tests. A dichotomous variable was constructed for current life expectancy perception, creating a subgroup that was pessimistic (``live less than 6 months,''``live 6 months,''``live a year,'' and``live a few years'') versus another subgroup that was optimistic (``live many years but not into old age'' and``live well into old age''). Three logistic regression models were constructed using this dichotomized, current life-expectancy variable as the dependent variable. Any variable that exhibited a significant (P .05) bivariate association with life expectancy perceptions, at any time, was eligible for entry. Perceptions about time periods in the past were assessed, and significant bivariate associations were estimated, but these separate analyses were used only to expand the pool of potentially explanatory variables and not for any other purpose because of the likelihood of recall bias. All eligible sociodemographic variables were entered into the first model; all eligible HIV-disease severity variables were entered into the second model; all significant (P .05) variables from models 1 and 2 were entered into the third model. The odds ratios and P values for all variables are reported for each model. The same dichotomized, current life-expectancy variable was used for c 2 comparisons of antiretroviral medication and sexual risk behavior adherence rates. All data were managed and analyzed using a combination of Epi Info Version 6 (Centers for Disease Control and Prevention, Atlanta, GA) and SYSTAT/PC version 9.0 (SPSS Inc., Chicago, Ill).
RESULTS
Responders and Nonresponders
Of the 295 anonymous questionnaires that were mailed, 220 (75%) were returned. A total of 199 identifying postcards were returned separately. Data provided by ActionAIDS, using postcard identifiers, indicated that responders and nonresponders were similar in age, gender, education, HIV risk behavior, medical, mental health, and life management needs, length of time seropositive, and CD4 cell counts. Responders were less likely than nonresponders to be nonwhite (59% vs 73%; P = .03) and responders' incomes were higher than nonresponders' ($10,743.27 vs $8,934.18; P = .04).
Respondents' sociodemographic and HIV-disease severity characteristics as self-reported on questionnaires are shown in Table 1 . A majority of respondents were nonwhite, almost a quarter were women, and over half reported annual incomes <$10,000. A majority reported sex risk, with or without drug use, as the risk behavior leading to their HIV infection; 14% reported injection drug use only. Table 2 lists word descriptors of HIV/AIDS categorized by whether they are negative, ambivalent, or positive. Preferred word descriptors, by category, are reported for the time after finding out about HIV seropositivity (``After HIV'') and currently (``At time of study''), as are P values for across-time comparisons. All comparisons were significantly different, except for 1 ambivalent descriptor. In general, negative descriptors were less common and positive descriptors more common currently, when compared with the time following discovery of HIV serostatus. Findings about ambivalent descriptors were inconsistent. For example, participants reported significantly less fear, depression, anger, shock, confusion, and frustration, as well as significantly more hope, readiness to live, and forward vision, with a sense that they'd been given a second chance. At the same time, they reported similar levels of 
Word Descriptions of HIV/AIDS
Beliefs about Life Expectancy
Data from all participants indicated that the mean rating of the belief-about-current-life-expectancy variable was 3.99 (SD, 0.77). Most participants, then, reported thinking that they would live many years; a surprising proportion, 27%, thought they would live well into old age. Bivariate analyses indicated that race, gender, and CD4 cell count variables were associated with beliefs about life expectancy (Table 3) . Nonwhites, women, and individuals with CD4 cell counts >200 cells/mL 3 were significantly more likely to be optimistic. When sociodemographic variables having any significant association with prognostic beliefs, at any time, were entered into a logistic regression modeling of optimism, race, education, and injection drug use history were found to be significantly, independently associated (Table 4) . Again, nonwhites were more optimistic, as were those who were more educated and those with injection drug use histories. Focus group participants with injection drug use histories reported that seroconversion had led many of them to quit using drugs and thus had improved their outlook. CD4 count was the only HIV disease severity variable found to be significantly, independently associated with beliefs about life expectancy (Table 4 ). Higher CD4 counts were associated with optimism. Significant variables from the 2 prior models were placed into a final model. Race, education, and CD4 cell counts remained significantly, independently associated with optimism (Table 4) .
Medication and Sexual Risk Behavior Adherence
Fourteen (7%) and 56 (26%) respondents self-reported not taking antiretroviral medications and not having sex, respectively. These subgroups were removed from subsequent analyses. Those not taking versus taking medication trended toward being more pessimistic (43% vs 24%; P = .11). Those not having versus having sex were significantly more pessimistic (36% vs 22%; P = .05).
Of those taking antiretrovirals, 48 (22%) of 216 respondents self-reported medication nonadherence. Bivariate analyses, employing all descriptors from Table 1 , indicated that no variable was associated with nonadherence (all P values >.35, except for age, P = .13). Those who were optimistic, however, reported significantly more medication nonadherence than those who were pessimistic (26% vs 13%; P = .04).
Of those having sex, 82 (51%) of 161 respondents selfreported nonadherence to safe sex precautions. Bivariate analyses, employing all descriptors from Table 1, indicated that no variable was associated with safe sex nonadherence (all P values >.20, except for age, P = .15). Those who were optimistic, however, reported significantly more safe sex nonadherence than did those who were pessimistic (57% vs 29%; P = .004).
DISCUSSION
Data from seropositive individuals in this case management organization revealed substantial and significant shifts in perceived optimism about HIV/AIDS. Participants not only used more positive and fewer negative words to describe HIV/AIDS than they had in the past but also reported that they believed they would live many more years, perhaps even into old age. This optimism was true for all groups, although persons of color, those with more education, and those with less immunocompromise were significantly more likely to be optimistic.
Although having more education and better immune status might reasonably lead to an increase in prognostic optimism, whether by improved access, better understanding of the disease process, or simply having knowledge of one's degree of immunocompromise, it is less clear why persons of color, as well as, in unadjusted findings, women and those with injection drug use histories, are more optimistic. As noted earlier, these subgroups have been underrepresented in clinical trials of HAART and have benefited less, or more slowly, from the new treatment regimens. This, as well as the fact that data suggest HAART may fail in approximately half of individuals, is not reflected in the optimistic findings from this study. 22 Individual-level information and/or care that seropositive individuals receive about and/or for their HIV-disease severity, then, may not be the information that primarily affects their selfperceptions of prognosis. Overly enthusiastic lay and medical press reporting on advances in HIV/AIDS therapy may skew seropositive individuals' self-perceptions in a direction that is similarly enthused. Population-based secular trends may overwhelm individual-level facts. Clinicians may need to spend more time educating patients about their HIV disease profiles, and explanations of changeable CD4 cell counts and complex viral load trends may require ongoing and simplified discussions. Such ongoing education is particularly important in light of the finding that there is significantly higher medication and safe sex nonadherence in those who are optimistic about their life expectancy. Optimism, whether based on real, individual clinical data or generalization from secular trends, may improve perceived quality of life, but it also may have these unintended consequences that, perhaps, should be anticipated and dealt with in clinical interactions. Whether optimism engenders less focus on one's status as infected with HIV, and thus forgetfulness about the possibility of HIV progression or wishful thinking about the actuality of one's infectiousness, is not known, insofar as it has not been studied before and was not assessed as part of this study. Qualitative work is needed to link external associations with internal motivations; thus, mixed-method studies, with increased power for quantitative assessments, should investigate this further. Until then, it may be prudent to remember that good news delivered to patients should be accompanied by advice about the need for continued, vigilant medication and safe sex adherence.
The findings from this study suggest that a new conceptual model of HIV infection prognosis may exist. To figuratively represent this new model, older models of terminal illness, such as one described by Rando, may need to be adapted to an HIV-specific context (Fig. 1) . 23 Within this new conceptual model, an individual may initially go through an``acute adjustment'' phase following discovery of seropositive status, after which s/he comes to perceive the prognosis of her/his infection within a Rando-based framework of``living-dying'' (although alive for the foreseeable future, one fears s/he could die at any time) or``terminal'' (one believes s/he will die in the near future). With time and/or treatment, however, the newly seropositive individual can die, worsen, remain the same, or improve. If s/he survives the acute adjustment phase, which is the usual scenario, her/his prognostic perception can remain the same or transition to another category, the possibilities of which might include an added category referred to in our conceptualization as``re-living.'' This category is similar to the seronegative``living'' category (death is considered a possible although distant likelihood, probably unrelated to HIV/AIDS). Although our data suggest that such a new model may exist, future study is needed to validate it. This study has limitations. All participants were selected from 1 urban case management organization in an effort to increase representation of women, people of color, and injection drug users. While representation may have increased, generalizability was reduced, so these findings need to be confirmed in other sample types. Until then, these findings actually may suggest varied interpretations of the data that are important to consider. For example, groups not disadvantaged enough to require case management could perceive prognosis of HIV infection more optimistically than did this sample and thus may require greater attention to adherence issues.
Alternatively, the optimism of this more-disadvantaged sample may indicate that case management organizations successfully reduce the subsistence needs of socially disadvantaged groups that compete with adequate access to quality medical care. 24, 25 This increase in optimism that may result perhaps suggests that case management organizations also must gauge adherence issues more carefully and advise clients more actively. We did, however, exclude clients with the``highest levels of need.'' These excluded clients may have been more pessimistic, and excluding them may have biased findings in the direction of greater optimism. Obviously, then, these limitations to our findings urge investigators to study prognostic perceptions more carefully not only in more generalizable communitybased samples but in the case management arena as well. Another limitation is that data were self-reported. As a result, the less strong/consistent association between HIVrelated clinical variables and prognostic beliefs may be due to noninformative misclassification bias resulting from CD4 cell counts/viral loads having been reported incorrectly, or to lack of power resulting from a large number of missing values for CD4 cell count/viral load variables.
Response bias is always a potential concern in survey studies. Although our response rate was very high, and similarity between responders and nonresponders notable, there may be some unmeasured differences between groups that may have biased results in unclear directions. It is notable, however, that many of the self-reported characteristics mirrored those of AIDS cases reported to the City of Philadelphia at the time of the study. 26 Word descriptors of respondents' experience with HIV/ AIDS, reported for the time after finding out that one was HIV infected, were describing perceptions that had occurred, on average, 8 years ago. Concern about recall bias could lead one to question these findings, particularly those that compare rates of past versus current descriptor use. Consistency of findings and similarity to reports from focus groups completed in preparation for this study, however, temper this tendency to question. Descriptor use, then, appears to be clearly different; bias was more likely to have influenced the magnitude of the difference, although the direction of the bias is unclear such that the magnitude of the difference may actually be greater. Consequently, we suggest that these descriptor results be used to provide a qualitative picture of the optimism perceived by many in the study.
Medication and safe sex nonadherence was assessed simplistically. While such assessments may be appropriate in an exploratory study seeking to identify the possibility that prognostic perceptions might influence nonadherence, confirmatory studies should employ better approaches. For example, confirmatory study of medication nonadherence might assess pill counts or MEMcaps data over time. The assessment of safe sex nonadherence might employ capture of the actual number of unprotected sex acts over a specified time period, taking into account the number of partners, the level of risk imparted by each partner, and the level of risk imparted by the acts in which a respondent has engaged with each partner.
Finally, this study employed a cross-sectional design; establishing that associations are causal in nature must await future studies.
Evaluation of seropositive individuals' prognostic beliefs may have a number of helpful applications. First, elicitation of beliefs allows description of how the selfperception of HIV/AIDS as an illness has changed for those with the illness, both on an individual level and across (sub)populations. Such a portrayal provides an evolving snapshot of how advances in the treatment of HIV/AIDS, as well as public characterizations of these advances, may affect individual self-perceptions. Second, elicitation of prognostic beliefs allows assessment of how individual-level variables may affect self-perceptions, perhaps in ways that are at odds with the severity of one's HIV infection Ð information that may be of particular interest to clinicians who counsel patients. Finally, obtaining prognostic self-assessments may allow riskstratification for undesired consequences such as medication and safe sex nonadherence.
